100005-23-0 Usage
General Description
2-AMINO-4-(4-METHOXYPHENYL)-5-METHYLTHIOPHENE-3-CARBONITRILE is a chemical compound that consists of a thiophene ring with an amino group at the 2-position, a methyl group at the 5-position, and a 4-methoxyphenyl group at the 4-position. It also contains a cyano group at the 3-position of the thiophene ring. 2-AMINO-4-(4-METHOXYPHENYL)-5-METHYLTHIOPHENE-3-CARBONITRILE is used in the synthesis of various pharmaceuticals and agrochemicals and has potential applications in the field of medicinal chemistry and drug discovery. Its unique structure and properties make it a valuable building block for the development of new compounds with potential biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 100005-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,0,0 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 100005-23:
(8*1)+(7*0)+(6*0)+(5*0)+(4*0)+(3*5)+(2*2)+(1*3)=30
30 % 10 = 0
So 100005-23-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H12N2OS/c1-8-12(11(7-14)13(15)17-8)9-3-5-10(16-2)6-4-9/h3-6H,15H2,1-2H3
100005-23-0Relevant articles and documents
PFKFB3 INHIBITORS AND THEIR USES
-
Page/Page column 132; 151, (2020/05/21)
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, methods of preparation thereof, methods for their use as therapeutic agents, and methods of preparation of a medicament for use in therapy, as well as kits and other inventiions comprising such PFKFB3 inhibitors. These PFKFB3 inhibitors are useful for the treatment and prophylaxis of cancer, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, multiple sclerosis, metabolic diseases, inhibition of angiogenesis and other diseases and conditions, where the modulation of PFKFB3 and/or PFKFB4 has beneficial effect as well as neuroprotection.
